Ads
related to: list of cranium removals cancer risk reduction medications
Search results
Results From The WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
Essiac – a blended herbal tea devised in the early 20th century and promoted as a cancer cure. The U.S. Food and Drug Administration include Essiac in a list of "Fake Cancer 'Cures' Consumers Should Avoid". [71] Fermented wheat germ extract (FWGE) – a concentrated extract of wheat germ sold with the brand names Avemar and Awge.
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Hypophysectomy is the surgical removal of the hypophysis (pituitary gland). It is most commonly performed to treat tumors, especially craniopharyngioma tumors. [1] Sometimes it is used to treat Cushing's syndrome due to pituitary adenoma [2] or Simmond's disease [3] It is also applied in neurosciences (in experiments with lab animals) to understand the functioning of hypophysis.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
In March 2011, investigators from Australia and several other countries published the results of the DECRA [5] trial in The New England Journal of Medicine.This was a randomized trial comparing decompressive craniectomy to best medical therapy run between 2002 and 2010 to assess the optimal management of patients with medically refractory ICP following diffuse non-penetrating head injury.